Francis D. Gibbons

TL;DR: In this paper, methods for the therapeutic administration of bispecific scFv conjugates as single doses at at least weekly intervals are presented. But the authors do not specify a single loading dose for each conjugate.

TL;DR: AZD0466 demonstrated greater monotherapy activity than platinum/etoposide chemotherapy regimen or venetoclax monotherapy in 6 out of 11 SCLC PDX models and has therapeutic potential as monotherapy and a combinatorial agent to increase the depth and duration of response to standard of care and BTK inhibitors in hematological tumors.

TL;DR: In this article, the authors proposed methods for treating patients which comprises methods for predicting responses of cells such as tumor cells, to treatment with therapeutic agents, and also comprises predictive methods for cellular responsiveness in which computation of a NAS or NIS value for the cells (e.g., tumor cells) is combined with use of a statistical classification algorithm.

TL;DR: A potent small molecule that rapidly induces apoptosis in preclinical hematologic tumor models and displays the hallmarks of a bona fide BH3 mimetic is developed, highlighting the therapeutic potential of a dual Bcl-2/xL inhibitor to be used as a foundation therapy across a broad range of hematological tumor types as well as combat resistance to other Bh3 mimetics and targeted therapies.

TL;DR: The discovery and characterization of AZD0364, a novel, reversible, ATP-competitive ERK1/2 inhibitor with high potency and kinase selectivity, and selumetinib combination, which enhances efficacy in KRAS-mutant preclinical models that are moderately sensitive or resistant to MEK 1/2 inhibition.